In this study, we explored the modified leucine amino acid, ADLL, for its potential therapeutic effects in a mouse model of Sandhoff disease, as it had previously provided beneficial effects in another lysosomal storage disease, NPC1 (observational clinical study) [16] and in Tangier disease patient cells [17]. This evidence concerns the gene NPC1 and lysosomal storage disease.